A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

TY - JOUR

T1 - A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

AU - Meltzer, Herbert Y.

AU - Bonaccorso, Stefania

AU - Bobo, William V.

AU - Chen, Yuejin

AU - Jayathilake, Karuna

PY - 2011/12

Y1 - 2011/12

N2 - Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method:This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F-4,F-434=4.7), body mass index (BMI) (F-4,F-424=5.1), glycosylated hemoglobin (HgbA1c) (F-4,F-427=4.3), total cholesterol (F-4,F-429=4.4), TG (F-4,F-426=5.9), and TG/HDL-C ratio (F-4,F-426=4.3) (P

AB - Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method:This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F-4,F-434=4.7), body mass index (BMI) (F-4,F-424=5.1), glycosylated hemoglobin (HgbA1c) (F-4,F-427=4.3), total cholesterol (F-4,F-429=4.4), TG (F-4,F-426=5.9), and TG/HDL-C ratio (F-4,F-426=4.3) (P

U2 - 10.4088/JCP.10m05997

DO - 10.4088/JCP.10m05997

M3 - Article

VL - 72

SP - 1602

EP - 1610

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

IS - 12

ER -